Ascendis Pharma A/S
ASND
22 hedge funds and large institutions have $281M invested in Ascendis Pharma A/S in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 6 closing their positions.
53% more capital invested
Capital invested by funds: $184M → $281M (+$97.2M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less funds holding
Funds holding: 23 → 22 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$4.43M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.62M |
| 3 |
NC
Nexthera Capital
New York
|
+$2.41M |
| 4 |
Millennium Management
New York
|
+$1.26M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$746K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sculptor Capital
New York
|
-$1.99M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.81M |
| 3 |
SCM
Sio Capital Management
New York
|
-$1.49M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$1.33M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.01M |
ASND Hedge Fund Activity: Q3 2016 in Review
22 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q3 2016, worth a combined $281M — up 53% from $184M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ASND and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 2 added.
The largest buyer was RA Capital Management, adding an estimated $4.43M. The largest seller was Sculptor Capital, exiting entirely with an estimated $1.99M sold.
- 22 institutional investors held Ascendis Pharma A/S (ASND) as of Q3 2016, down from 23 in Q2 2016.
- Funds reported $281M of Ascendis Pharma A/S stock for Q3 2016, up 53% quarter-over-quarter.
- 5 funds opened new Ascendis Pharma A/S positions in Q3 2016 and 6 closed out, a net change of -1 holder.
- The largest Ascendis Pharma A/S buyer in Q3 2016 was RA Capital Management, an estimated $4.43M added.
- The largest Ascendis Pharma A/S seller in Q3 2016 was Sculptor Capital, an estimated $1.99M sold.
Based on aggregated 13F filings for Q3 2016.